Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 68

1.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; for the Gruppo Italiano Mammella (GIM) investigators.

Lancet. 2015 Feb 27. pii: S0140-6736(14)62048-1. doi: 10.1016/S0140-6736(14)62048-1. [Epub ahead of print]

PMID:
25740286
2.

Triple positive breast cancer: a distinct subtype?

Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, Sergi D, Botti C, Michelotti A, Moscetti L, Mariani L, Izzo F, D'Onofrio L, Sperduti I, Conti F, Rossi V, Cassano A, Maugeri-Saccà M, Mottolese M, Marchetti P.

Cancer Treat Rev. 2015 Feb;41(2):69-76. doi: 10.1016/j.ctrv.2014.12.005. Epub 2014 Dec 19. Review.

3.

Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an italian survey.

Tinari N, Fanizza C, Romero M, Gambale E, Moscetti L, Vaccaro A, Seminara P, Longo F, Gori S, Vici P, Gamucci T, Mauri M, Laudadio L, Nuzzo A, Fabbri MA, Fattoruso SI, Mazzilli L, Grassadonia A, Cianchetti E, Natoli C.

Clin Breast Cancer. 2015 Apr;15(2):e131-7. doi: 10.1016/j.clbc.2014.10.005. Epub 2014 Oct 22.

4.

The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.

Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, Ramieri MT, Di Lauro L, Sergi D, Bartucci M, Dattilo R, Pagliuca A, De Maria R, Maugeri-Saccà M.

Oncotarget. 2014 Oct 30;5(20):9619-25.

5.

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.

Vici P, Pizzuti L, Natoli C, Moscetti L, Mentuccia L, Vaccaro A, Sergi D, Di Lauro L, Trenta P, Seminara P, Santini D, Iezzi L, Tinari N, Bertolini I, Sini V, Mottolese M, Giannarelli D, Giotta F, Maugeri-Saccà M, Barba M, Marchetti P, Michelotti A, Sperduti I, Gamucci T.

Breast Cancer Res Treat. 2014 Oct;147(3):599-607. doi: 10.1007/s10549-014-3133-1. Epub 2014 Sep 19.

6.

Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients.

Vici P, Pizzuti L, Gamucci T, Sergi D, Conti F, Zampa G, Del Medico P, De Vita R, Pozzi M, Botti C, Di Filippo S, Tomao F, Sperduti I, Di Lauro L.

J Cancer. 2014 Apr 25;5(6):398-405. doi: 10.7150/jca.9132. eCollection 2014.

7.

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, Di Lauro L, Fabi A, Tonini G, Sini V, Salesi N, Ferrarini I, Vaccaro A, Pavese I, Veltri E, Moscetti L, Marchetti P, Vici P.

J Cancer. 2014 Mar 20;5(5):320-7. doi: 10.7150/jca.8748. eCollection 2014.

8.

Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.

Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; “FOLLOW-UP” Study Group.

PLoS One. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014.

9.

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.

Sperduti I, Vici P, Tinari N, Gamucci T, De Tursi M, Cortese G, Grassadonia A, Iacobelli S, Natoli C.

J Exp Clin Cancer Res. 2013 Nov 11;32:89. doi: 10.1186/1756-9966-32-89. Review.

10.

Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis.

Grande R, Corsi D, Mancini R, Gemma D, Ciancola F, Sperduti I, Rossi L, Fabbri A, Diodoro MG, Ruggeri E, Zampa G, Bianchetti S, Gamucci T.

PLoS One. 2013 Dec 5;8(12):e80188. doi: 10.1371/journal.pone.0080188. eCollection 2013.

11.

A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice.

Barni S, Lorusso V, Giordano M, Sogno G, Gamucci T, Santoro A, Passalacqua R, Iaffaioli V, Zilembo N, Mencoboni M, Roselli M, Pappagallo G, Pronzato P.

Med Oncol. 2014 Jan;31(1):797. doi: 10.1007/s12032-013-0797-z. Epub 2013 Dec 5.

PMID:
24307348
12.

Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control.

La Verde N, Moretti A, Farina G, Dazzani MC, Gamucci T, Borgonovo K, Botta M, Salesi N, Zuradelli M, Pavese I, Barbieri E, Cretella E, Saladino T, Varese P, Traverso ES, Addamo G, Ciccarese M, Rispoli AI, Pellegrino A, Mentuccia L, Girelli S, Piva S, Di Maio M.

Future Oncol. 2013 Dec;9(12):1841-8. doi: 10.2217/fon.13.216.

PMID:
24295414
13.

Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.

Gamucci T, Moscetti L, Mentuccia L, Pizzuti L, Mauri M, Zampa G, Pavese I, Sperduti I, Vaccaro A, Vici P.

J Cancer Res Clin Oncol. 2014 Feb;140(2):221-6. doi: 10.1007/s00432-013-1556-4. Epub 2013 Nov 29.

14.

Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.

Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo A, Febbraro A, Satolli MA, Bertocchi P, Catalano V, Giommoni E, Comandone A, Maiello E, Riccardi F, Ferrara R, Trogu A, Berardi R, Leo S, Bertolini A, Angelini F, Cinieri S, Russo A, Pisconti S, Brunetti AE, Azzariti A, Santini D.

PLoS One. 2013 Oct 28;8(10):e74402. doi: 10.1371/journal.pone.0074402. eCollection 2013.

15.

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M.

World J Gastroenterol. 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511.

16.

Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

Grande R, Gemma D, Sperduti I, Gelibter A, Giampaolo MA, Trombetta G, Nelli F, Gamucci T.

Springerplus. 2013 Apr 25;2(1):185. doi: 10.1186/2193-1801-2-185. Print 2013 Dec.

17.

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.

Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y. Epub 2013 Apr 20.

18.

Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.

Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I, Franco D, Ruggeri EM.

Invest New Drugs. 2013 Aug;31(4):1035-43. doi: 10.1007/s10637-013-9936-9. Epub 2013 Feb 17.

PMID:
23417697
19.

Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis.

Gamucci T, Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Longo F, Fabbri MA, Giampaolo MA, Mentuccia L, Di Lauro L, Vici P.

J Cancer Res Clin Oncol. 2013 May;139(5):853-60. doi: 10.1007/s00432-013-1388-2. Epub 2013 Feb 15.

20.

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.

Bisagni G, Musolino A, Panebianco M, De Matteis A, Nuzzo F, Ardizzoni A, Gori S, Gamucci T, Passalacqua R, Gnoni R, Moretti G, Boni C.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1051-7. doi: 10.1007/s00280-013-2100-6. Epub 2013 Feb 3.

PMID:
23377310
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk